Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development (Q38059059)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

27 August 2017

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development (English)

1 reference

Europe PubMed Central

27 August 2017

1 reference

based on heuristic

inferred from title

3

object named as

Vidadi Yusibov

1 reference

Europe PubMed Central

27 August 2017

author name string

Natasha Kushnir

1

1 reference

Europe PubMed Central

27 August 2017

Stephen J Streatfield

2

1 reference

Europe PubMed Central

27 August 2017

language of work or name

0 references

publication date

6 November 2012

1 reference

Europe PubMed Central

27 August 2017

1 reference

Europe PubMed Central

27 August 2017

31

1 reference

Europe PubMed Central

27 August 2017

58-83

1 reference

Europe PubMed Central

27 August 2017

1

1 reference

Europe PubMed Central

27 August 2017

Vaccines: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Application of recombinant DNA techniques in the development of viral vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particles: passport to immune recognition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particles: flexible platforms for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virus-like particles containing M2 induce broadly cross protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recent advances with a virosomal hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A plant-derived edible vaccine against hepatitis B virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity in humans of an edible vaccine for hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Theoretical studies of viral capsid proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus assembly, allostery and antivirals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production of mink enteritis parvovirus empty capsids by expression in a baculovirus vector system: a recombinant vaccine for mink enteritis parvovirus in mink.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Large scale production and downstream processing of a recombinant porcine parvovirus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production of porcine parvovirus empty capsids with high immunogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Hepatitis B surface antigen. Role of lipids in maintaining the structural and antigenic properties of protein components

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Reconstitution of hepatitis B surface antigen proteins into phospholipid vesicles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Antigenicity of hepatitis B surface antigen proteins reconstituted with phospholipids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Hepatitis B surface antigen polypeptide micelles from antigen expressed in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Hepatitis B polypeptide vaccine preparation in micelle form

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Hepatitis B surface antigen: an unusual secreted protein initially synthesized as a transmembrane polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of hepatitis B virus surface antigen in yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Synthesis in animal cells of hepatitis B surface antigen particles carrying a receptor for polymerized human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

The virus of hepatitis, type B (first of two parts).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

The virus of hepatitis, type B. (Second of two parts)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Molecular characterization of recombinant Hepatitis B surface antigen from Chinese hamster ovary and Hansenula polymorpha cells by high-performance size exclusion chromatography and multi-angle laser light scattering.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human respiratory syncytial virus vaccine antigen produced in plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Peptide-based candidate vaccine against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Efficient production of chimeric human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Plant-produced potato virus X chimeric particles displaying an influenza virus-derived peptide activate specific CD8+ T cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particles as a vaccine delivery system: myths and facts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virus-like particle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Self-assembly of severe acute respiratory syndrome coronavirus membrane protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virus matrix protein is the major driving force in virus budding.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production and characterization of simian--human immunodeficiency virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembly of human severe acute respiratory syndrome coronavirus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Efficient assembly and release of SARS coronavirus-like particles by a heterologous expression system.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Ebola virus VP40-induced particle formation and association with the lipid bilayer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembly and biological and immunological properties of Newcastle disease virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Requirements for the assembly and release of Newcastle disease virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Versatile virus-like particle carrier for epitope based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human papillomavirus infection and the development of cervical cancer and related genital neoplasias

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembly of truncated HCV core antigen into virus-like particles in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

M2e-based universal influenza A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Microbial production of virus-like particle vaccine protein at gram-per-litre levels.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production and purification of SV40 major capsid protein (VP1) in Escherichia coli strains deficient for the GroELS chaperone machine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression and self-assembly of cowpea chlorotic mottle virus-like particles in Pseudomonas fluorescens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Plants as biofactories

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recent progress in the development of plant derived vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

The expression of hybrid HIV:Ty virus-like particles in yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production of L1 protein from different types of HPV in Pichia pastoris using an integrative vector.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression and purification of human papillomavirus 18 L1 virus-like particle from saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Norovirus capsid protein expressed in yeast forms virus-like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Growth rate control in fed-batch cultures of recombinant Saccharomyces cerevisiae producing hepatitis B surface antigen (HBsAg)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Characterization of the HCV core virus-like particles produced in the methylotrophic yeast Pichia pastoris.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of heterologous genes in Saccharomyces cerevisiae from vectors utilizing the glyceraldehyde-3-phosphate dehydrogenase gene promoter

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Exploiting the yeast L-A viral capsid for the in vivo assembly of chimeric VLPs as platform in vaccine development and foreign protein expression

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Generation of virus-like particles consisting of the major capsid protein VP1 of goose hemorrhagic polyomavirus and their application in serological tests

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

The protease and gag gene products of the human immunodeficiency virus: authentic cleavage and post-translational modification in an insect cell expression system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recombinant Norwalk virus-like particles given orally to volunteers: phase I study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Norovirus vaccine against experimental human Norwalk Virus illness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Synthesis of rotavirus-like particles in insect cells: comparative and quantitative analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Nasal immunization of mice with virus-like particles protects offspring against rotavirus diarrhea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Oral and intraperitoneal immunization with rotavirus 2/6 virus-like particles stimulates a systemic and mucosal immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Co-expression of the hepatitis B surface and core antigens using baculovirus multiple expression vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Construction and characterization of insect cell-derived influenza VLP: cell binding, fusion, and EGFP incorporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Respiratory syncytial virus infection in elderly and high-risk adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Ebola and Marburg virus-like particles activate human myeloid dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Protection against lethal challenge by Ebola virus-like particles produced in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particles of SARS-like coronavirus formed by membrane proteins from different origins demonstrate stimulating activity in human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Safety and immunogenicity of a candidate parvovirus B19 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression, purification and characterization of enterovirus-71 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

An overview of the evolution of enterovirus 71 and its clinical and public health significance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembly of herpes simplex virus type 1 capsids using a panel of recombinant baculoviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Effect of dose and long-term storage on the immunogenicity of murine polyomavirus VP1 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Self-assembly of the JC virus major capsid protein, VP1, expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Roles of disulfide linkage and calcium ion-mediated interactions in assembly and disassembly of virus-like particles composed of simian virus 40 VP1 capsid protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Protective efficacy of virus-like particles for bluetongue disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenic and protective properties of chicken anaemia virus proteins expressed by baculovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Simultaneous expression of recombinant baculovirus-encoded chicken anaemia virus (CAV) proteins VP1 and VP2 is required for formation of the CAV-specific neutralizing epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Effect of MOI ratio on the composition and yield of chimeric infectious bursal disease virus-like particles by baculovirus co-infection: deterministic predictions and experimental results

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Noninfectious virus-like particle antigen for detection of swine vesicular disease virus antibodies in pigs by enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Characterization of protection afforded by a bivalent virus-like particle vaccine against bluetongue virus serotypes 1 and 4 in sheep

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity of a recombinant Pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Secretion of noninfectious dengue virus-like particles and identification of amino acids in the stem region involved in intracellular retention of envelope protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A strong endoplasmic reticulum retention signal in the stem-anchor region of envelope glycoprotein of dengue virus type 2 affects the production of virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Murray Valley encephalitis virus recombinant subviral particles protect mice from lethal challenge with virulent wild-type virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Multivesicular bodies as a platform for formation of the Marburg virus envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Ebola virus-like particles protect from lethal Ebola virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Mapping of a region of Ebola virus VP40 that is important in the production of virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Role of natural killer cells in innate protection against lethal ebola virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and the S segments of Hantaan virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Nipah virus: a recently emergent deadly paramyxovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Nipah virus--a potential agent of bioterrorism?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Vaccine potential of Nipah virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Respiratory syncytial virus (RSV) fusion protein expressed by recombinant Sendai virus elicits B-cell and T-cell responses in cotton rats and confers protection against RSV subtypes A and B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Single intranasal immunization with recombinant adenovirus-based vaccine induces protective immunity against respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of HIV-1 antigens in plants as potential subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production of recombinant HIV-1/HBV virus-like particles in Nicotiana tabacum and Arabidopsis thaliana plants for a bivalent plant-based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity and tolerance following HIV-1/HBV plant-based oral vaccine administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Hybrid viral vectors for vaccine and antibody production in plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Advances in alfalfa mosaic virus-mediated expression of anthrax antigen in planta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunization against rabies with plant-derived antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity of peptides derived from a fibronectin-binding protein of S. aureus expressed on two different plant viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A chimaeric plant virus vaccine protects mice against a bacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Plant-derived vaccine protects target animals against a viral disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Characterization of the immune response to canine parvovirus induced by vaccination with chimaeric plant viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Effect of priming/booster immunisation protocols on immune response to canine parvovirus peptide induced by vaccination with a chimaeric plant virus construct

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Oral immunogenicity of human papillomavirus-like particles expressed in potato

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production of human papillomavirus type 16 virus-like particles in transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A DNA replicon system for rapid high-level production of virus-like particles in plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production of Rotavirus-Like Particles in Tomato (Lycopersicon esculentum L.) Fruit by Expression of Capsid Proteins VP2 and VP6 and Immunological Studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity and virus-like particle formation of rotavirus capsid proteins produced in transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Oral immunization with hepatitis B surface antigen expressed in transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of hepatitis B surface antigen in transgenic plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Production of hepatitis B surface antigen in transgenic plants for oral immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity of transgenic plant-derived hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Structural characterization of plant-derived hepatitis B surface antigen employed in oral immunization studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

The use of viral vectors to produce hepatitis B virus core particles in plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particles production in green plants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Protection of mice against challenge with foot and mouth disease virus (FMDV) by immunization with foliar extracts from plants infected with recombinant tobacco mosaic virus expressing the FMDV structural protein VP1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector*1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Induction of protective immunity in swine by recombinant bamboo mosaic virus expressing foot-and-mouth disease virus epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Development of Tobacco necrosis virus A as a vector for efficient and stable expression of FMDV VP1 peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Structural and biological properties of Cucumber mosaic virus particles carrying hepatitis C virus-derived epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

In vitro stability of Cucumber mosaic virus nanoparticles carrying a Hepatitis C virus-derived epitope under simulated gastrointestinal conditions and in vivo efficacy of an edible vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Epitope presentation system based on cucumber mosaic virus coat protein expressed from a potato virus X-based vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Improvement of PVX/CMV CP expression tool for display of short foreign antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Cucumber mosaic virus as the expression system for a potential vaccine against Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Engineered synthetic virus-like particles and their use in vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virosomes as a vaccine adjuvant and carrier system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Formation of virosomes from influenza subunits and liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A new and versatile virosomal antigen delivery system to induce cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Hepatitis B vaccines: protective efficacy and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

FluBlok, a recombinant hemagglutinin influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Virus-like particle based vaccines for Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Human hepatitis B vaccine from recombinant yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Plasma-derived and yeast-derived hepatitis B vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

A vaccine against nicotine for smoking cessation: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Intracellular assembly and packaging of hepatitis B surface antigen particles occur in the endoplasmic reticulum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression and self-assembly of empty virus-like particles of hepatitis E virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

based on heuristic

inferred from DOI database lookup

Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis C virus structural proteins assemble into viruslike particles in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

based on heuristic

inferred from DOI database lookup

Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

based on heuristic

inferred from DOI database lookup

Virus spike protein complexes and virosomes as effective subunit vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.10.083

7 January 2021

based on heuristic

inferred from DOI database lookup

Purification and characterization of virus-like particles and pentamers produced by the expression of SV40 capsid proteins in insect cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plant-based vaccines against diarrheal diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adverse reactions and immune response to Heberbiovac-HB vaccine administered to infants simultaneously with DPT and VA-MENGOC-BC

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization and replicase activity of double-layered and single-layered rotavirus-like particles expressed from baculovirus recombinants

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant vaccine for canine parvovirus in dogs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The making and breaking of symmetry in virus capsid assembly: glimpses of capsid biology from cryoelectron microscopy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploiting the intracellular compartmentalization characteristics of the S. cerevisiae host cell for enhancing primary purification of lipid-envelope virus-like particles.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of the recombinant proteins of porcine circovirus type2 field isolate expressed in the baculovirus system

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and self-assembly of HCV structural proteins into virus-like particles and their immunogenicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flavivirus DNA vaccines: current status and potential

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polyoma virus major capsid protein, VP1. Purification after high level expression in Escherichia coli.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Formation of virus-like particles when the polyprotein gene (segment A) of infectious bursal disease virus is expressed in insect cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Process scale considerations in evaluation studies and scale-up.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant rabbit hemorrhagic disease virus capsid protein expressed in baculovirus self-assembles into viruslike particles and induces protection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of three-dimensional structure on the immunogenicity of a peptide expressed on the surface of a plant virus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production in yeast versus mammalian cells of the first recombinant DNA human vaccine and its proved safety, efficacy, and economy: hepatitis B vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production of immunogenic human papillomavirus-16 major capsid protein derived virus like particles.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Corrigendum to "Protection against lethal challenge by Ebola virus-like particles produced in insect cells" [Virology 383 (2009) 12-21]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure of hepatitis B surface antigen. Characterization of the lipid components and their association with the viral proteins.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of rotavirus VP2 produces empty corelike particles

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Application of the human hepatitis B virus core antigen from transgenic tobacco plants for serological diagnosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological properties of recombinant HBsAg produced in yeast

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assembly of double-shelled rotaviruslike particles by simultaneous expression of recombinant VP6 and VP7 proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression & immunogenicity of malaria merozoite peptides displayed on the small coat protein of chimaeric cowpea mosaic virus.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of hepatitis B surface antigen in yeast

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/23142589

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2012.10.083

1 reference

https://api.fatcat.wiki/v0/release/76uhezmiufgxzpycivjrjnvuzm

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_76uhezmiufgxzpycivjrjnvuzm

1 reference

https://api.fatcat.wiki/v0/release/76uhezmiufgxzpycivjrjnvuzm

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/76uhezmiufgxzpycivjrjnvuzm

30 July 2022

based on heuristic

mapped directly with Wikidata item

1 reference

https://api.fatcat.wiki/v0/release/76uhezmiufgxzpycivjrjnvuzm

30 July 2022

based on heuristic

mapped directly with Wikidata item

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38059059&oldid=1801707730"